The DOI matches its Crossref record; 126 of the 126 references it cites were found in a registry or an index.
Cognitive symptoms of Alzheimer’s disease: clinical management and prevention
Abstract
Alzheimer’s disease (AD) is a progressive neurodegenerative disease characterized by the accumulation of amyloid β in the form of extracellular plaques and by intracellular neurofibrillary tangles, with eventual neurodegeneration and dementia. There is currently no disease-modifying treatment though several symptomatic medications exist with modest benefit on cognition. Acetylcholinesterase inhibitors have a consistent benefit across all stages of dementia; their benefit in mild cognitive impairment and prodromal AD is unproven. Memantine has a smaller benefit on cognition overall which is limited to the moderate to severe stages, and the combination of a cholinesterase inhibitor and memantine may have additional efficacy. Evidence for the efficacy of vitamin E supplementation and medical foods is weak but might be considered in the context of cost, availability, and safety in individual patients. Apparently promising disease-modifying interventions, mostly addressing the amyloid cascade hypothesis of AD, have recently failed to demonstrate efficacy so novel approaches must be considered.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
Albert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., Gamst, A., Holtzman, D. M., Jagust, W. J., Petersen, R. C., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.008 · Cited by 10,152
Diagnostic and Statistical Manual of Mental Disorders (DSM-IV)
Hu, R. J. (2003) · Encyclopedia of the Neurological Sciences · doi:10.1016/b0-12-226870-9/01070-4 · Cited by 9,117
Glenner, G. G., & Wong, C. W. (1984) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(84)80190-4 · Cited by 5,404
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70299-6 · Cited by 4,806
Scheltens, P., Blennow, K., Breteler, M. M. B., de Strooper, B., Frisoni, G. B., Salloway, S., & Van der Flier, W. M. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01124-1 · Cited by 3,125
The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al. (2016) · Nature · doi:10.1038/nature19323 · Cited by 3,059
Scheuner, D., Eckman, C., Jensen, M., Song, X., Citron, M., Suzuki, N., Bird, T. D., Hardy, J., Hutton, M., Kukull, W., et al. (1996) · Nature Medicine · doi:10.1038/nm0896-864 · Cited by 2,599
2019 Alzheimer’s disease facts and figures.
Alzheimer's Association (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2019.01.010 · Cited by 2,461
Jack, C. R., Albert, M. S., Knopman, D. S., McKhann, G. M., Sperling, R. A., Carrillo, M. C., Thies, B., & Phelps, C. H. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.004 · Cited by 2,042
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1304839 · Cited by 1,960
Vitamin E and Donepezil for the Treatment of Mild Cognitive Impairment
Petersen, R. C., Thomas, R. G., Grundman, M., Bennett, D., Doody, R., Ferris, S., Galasko, D., Jin, S., Kaye, J., Levey, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050151 · Cited by 1,844
Klein, E. A., Thompson, I. M., Tangen, C. M., Crowley, J. J., Lucia, M. S., Goodman, P. J., Minasian, L. M., Ford, L. G., Parnes, H. L., Gaziano, J. M., et al. (2011) · JAMA · doi:10.1001/jama.2011.1437 · Cited by 1,787
Larson, E. B., Wang, L., Bowen, J. D., McCormick, W. C., Teri, L., Crane, P., & Kukull, W. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-144-2-200601170-00004 · Cited by 1,463
Tariot, P. N., Farlow, M. R., Grossberg, G. T., Graham, S. M., McDonald, S., Gergel, I., & for the Memantine Study Group (2004) · JAMA · doi:10.1001/jama.291.3.317 · Cited by 1,403
Donepezil for dementia due to Alzheimer’s disease.
Birks, J. S., & Harvey, R. J. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001190.pub3 · Cited by 1,200
Effects of Aerobic Exercise on Mild Cognitive Impairment: A Controlled Trial
Baker, L. D., Frank, L. L., Foster-Schubert, K., Green, P. S., Wilkinson, C. W., McTiernan, A., Plymate, S. R., Fishel, M. A., Watson, G. S., Cholerton, B. A., et al. (2010) · Archives of Neurology · doi:10.1001/archneurol.2009.307 · Cited by 1,171
McShane, R., Areosa Sastre, A., & Minakaran, N. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003154.pub5 · Cited by 1,155
The spectrum of behavioral changes in Alzheimer's disease
Mega, M. S., Cummings, J. L., Fiorello, T., & Gornbein, J. (1996) · Neurology · doi:10.1212/wnl.46.1.130 · Cited by 1,115
Leisure-time physical activity at midlife and the risk of dementia and Alzheimer's disease
Rovio, S., Kåreholt, I., Helkala, E.-L., Viitanen, M., Winblad, B., Tuomilehto, J., Soininen, H., Nissinen, A., & Kivipelto, M. (2005) · The Lancet Neurology · doi:10.1016/s1474-4422(05)70198-8 · Cited by 1,054
The role of brain vasculature in neurodegenerative disorders
Sweeney, M. D., Kisler, K., Montagne, A., Toga, A. W., & Zlokovic, B. V. (2018) · Nature Neuroscience · doi:10.1038/s41593-018-0234-x · Cited by 998
Zhao, Q.-F., Tan, L., Wang, H.-F., Jiang, T., Tan, M.-S., Tan, L., Xu, W., Li, J.-Q., Wang, J., Lai, T.-J., et al. (2016) · Journal of Affective Disorders · doi:10.1016/j.jad.2015.09.069 · Cited by 916
Physical Activity, Diet, and Risk of Alzheimer Disease
Scarmeas, N. (2009) · JAMA · doi:10.1001/jama.2009.1144 · Cited by 916
(2004) · The Lancet · doi:10.1016/s0140-6736(04)16499-4 · Cited by 892
Donepezil and memantine for moderate-to-severe Alzheimer's disease
Howard, R., McShane, R., Lindesay, J., Ritchie, C., Baldwin, A., Barber, R., Burns, A., Dening, T., Findlay, D., Holmes, C., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1106668 · Cited by 782
Docosahexaenoic Acid Supplementation and Cognitive Decline in Alzheimer Disease: A Randomized Trial
Quinn, J. F., Raman, R., Thomas, R. G., Yurko-Mauro, K., Nelson, E. B., Van Dyck, C., Galvin, J. E., Emond, J., Jack, C. R., Weiner, M., et al. (2010) · JAMA · doi:10.1001/jama.2010.1510 · Cited by 764
Alzheimer's disease drug development pipeline: 2019
Cummings, J., Lee, G., Ritter, A., Sabbagh, M., & Zhong, K. (2019) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2019.05.008 · Cited by 762
Impact of multiple pathologies on the threshold for clinically overt dementia
Kapasi, A., DeCarli, C., & Schneider, J. A. (2017) · Acta Neuropathologica · doi:10.1007/s00401-017-1717-7 · Cited by 739
Vascular dysfunction—The disregarded partner of Alzheimer's disease
Sweeney, M. D., Montagne, A., Sagare, A. P., Nation, D. A., Schneider, L. S., Chui, H. C., Harrington, M. G., Pa, J., Law, M., Wang, D. J. J., et al. (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.07.222 · Cited by 711
Exercise programs for people with dementia
Forbes, D., Forbes, S. C., Blake, C. M., Thiessen, E. J., & Forbes, S. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006489.pub4 · Cited by 631
Dysken, M. W., Sano, M., Asthana, S., Vertrees, J. E., Pallaki, M., Llorente, M., Love, S., Schellenberg, G. D., McCarten, J. R., Malphurs, J., et al. (2014) · JAMA · doi:10.1001/jama.2013.282834 · Cited by 628
Henderson, S. T., Vogel, J. L., Barr, L. J., Garvin, F., Jones, J. J., & Costantini, L. C. (2009) · Nutrition & Metabolism · doi:10.1186/1743-7075-6-31 · Cited by 548
Rivastigmine for Alzheimer’s disease.
Birks, J. S., Chong, L.-Y., & Grimley Evans, J. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001191.pub4 · Cited by 534
EFNS guidelines for the diagnosis and management of Alzheimer's disease
Hort, J., O’Brien, J. T., Gainotti, G., Pirttila, T., Popescu, B. O., Rektorova, I., Sorbi, S., Scheltens, P., & Dementia, O. B. O. T. E. S. P. O. (2010) · European Journal of Neurology · doi:10.1111/j.1468-1331.2010.03040.x · Cited by 490
Lamb, S. E., Sheehan, B., Atherton, N., Nichols, V., Collins, H., Mistry, D., Dosanjh, S., Slowther, A. M., Khan, I., Petrou, S., et al. (2018) · BMJ · doi:10.1136/bmj.k1675 · Cited by 417
Vitamin E for Alzheimer's dementia and mild cognitive impairment
Farina, N., Llewellyn, D., Isaac, M. G. E. K. N., & Tabet, N. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002854.pub5 · Cited by 413
Effects of vitamin E on stroke subtypes: meta-analysis of randomised controlled trials
Schurks, M., Glynn, R. J., Rist, P. M., Tzourio, C., & Kurth, T. (2010) · BMJ · doi:10.1136/bmj.c5702 · Cited by 380
Feldman, H. H., Ferris, S., Winblad, B., Sfikas, N., Mancione, L., He, Y., Tekin, S., Burns, A., Cummings, J., del Ser, T., et al. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70109-6 · Cited by 335
Hsu, W.-Y., Ku, Y., Zanto, T. P., & Gazzaley, A. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.04.016 · Cited by 330
Aerobic exercise for Alzheimer's disease: A randomized controlled pilot trial
Morris, J. K., Vidoni, E. D., Johnson, D. K., Van Sciver, A., Mahnken, J. D., Honea, R. A., Wilkins, H. M., Brooks, W. M., Billinger, S. A., Swerdlow, R. H., et al. (2017) · PLOS ONE · doi:10.1371/journal.pone.0170547 · Cited by 329
A Phase II Study of Fornix Deep Brain Stimulation in Mild Alzheimer’s Disease
Lozano, A. M., Fosdick, L., Chakravarty, M. M., Leoutsakos, J.-M., Munro, C., Oh, E., Drake, K. E., Lyman, C. H., Rosenberg, P. B., Anderson, W. S., et al. (2016) · Journal of Alzheimer's Disease · doi:10.3233/jad-160017 · Cited by 327
Galantamine for Alzheimer's disease and mild cognitive impairment
Loy, C., & Schneider, L. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001747.pub3 · Cited by 322
Patterson, C. (2018) · Cited by 311
Early-onset Alzheimer Disease and Its Variants
Mendez, M. F. (2019) · Continuum · doi:10.1212/con.0000000000000687 · Cited by 307
Efficacy of Souvenaid in Mild Alzheimer's Disease: Results from a Randomized, Controlled Trial
Scheltens, P., Twisk, J. W. R., Blesa, R., Scarpini, E., von Arnim, C. A. F., Bongers, A., Harrison, J., Swinkels, S. H. N., Stam, C. J., de Waal, H., et al. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2012-121189 · Cited by 306
Blacker, D. (1994) · Archives of Neurology · doi:10.1001/archneur.1994.00540240042014 · Cited by 275
Fiest, K. M., Roberts, J. I., Maxwell, C. J., Hogan, D. B., Smith, E. E., Frolkis, A., Cohen, A., Kirk, A., Pearson, D., Pringsheim, T., et al. (2016) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/cjn.2016.36 · Cited by 272
Cunnane, S. C., Courchesne‐Loyer, A., St‐Pierre, V., Vandenberghe, C., Pierotti, T., Fortier, M., Croteau, E., & Castellano, C. (2016) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12999 · Cited by 250
Rivastigmine for Alzheimer's disease
Birks, J. S., & Grimley Evans, J. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001191.pub3 · Cited by 247
Soininen, H., Solomon, A., Visser, P. J., Hendrix, S. B., Blennow, K., Kivipelto, M., Hartmann, T., Hallikainen, I., Hallikainen, M., Helisalmi, S., et al. (2017) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30332-0 · Cited by 241
Bullock, R., Touchon, J., Bergman, H., Gambina, G., He, Y., Rapatz, G., Nagel, J., & Lane, R. (2005) · Current Medical Research and Opinion · doi:10.1185/030079905x56565 · Cited by 228
A ketogenic drink improves brain energy and some measures of cognition in mild cognitive impairment
Fortier, M., Castellano, C., Croteau, E., Langlois, F., Bocti, C., St‐Pierre, V., Vandenberghe, C., Bernier, M., Roy, M., Descoteaux, M., et al. (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.12.017 · Cited by 216
Donepezil treatment of patients with MCI: A 48-week randomized, placebo-controlled trial
Doody, R. S., Ferris, S. H., Salloway, S., Sun, Y., Goldman, R., Watkins, W. E., Xu, Y., & Murthy, A. K. (2009) · Neurology · doi:10.1212/01.wnl.0000344650.95823.03 · Cited by 213
Alzheimer disease and aducanumab: adjusting our approach
Selkoe, D. J. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0205-1 · Cited by 208
Farina, N., Rusted, J., & Tabet, N. (2014) · International Psychogeriatrics · doi:10.1017/s1041610213001385 · Cited by 195
DONEPEZIL TREATMENT OF PATIENTS WITH MCI: A 48-WEEK RANDOMIZED, PLACEBO- CONTROLLED TRIAL
Crane, P. K. (2009) · Neurology · doi:10.1212/wnl.0b013e3181bd6c25 · Cited by 195
Workgroup, A. C. W. (2013) · Journal of the American Geriatrics Society · doi:10.1111/jgs.12226 · Cited by 188
Farlow, M. R., Salloway, S., Tariot, P. N., Yardley, J., Moline, M. L., Wang, Q., Brand-Schieber, E., Zou, H., Hsu, T., & Satlin, A. (2010) · Clinical Therapeutics · doi:10.1016/j.clinthera.2010.06.019 · Cited by 186
Exercise and BDNF reduce Aβ production by enhancing α‐secretase processing of APP
Nigam, S. M., Xu, S., Kritikou, J. S., Marosi, K., Brodin, L., & Mattson, M. P. (2017) · Journal of Neurochemistry · doi:10.1111/jnc.14034 · Cited by 185
Amyloid‐β immunotherapy for alzheimer disease: Is it now a long shot?
Panza, F., Lozupone, M., Seripa, D., & Imbimbo, B. P. (2019) · Annals of Neurology · doi:10.1002/ana.25410 · Cited by 178
Omega-3 fatty acids for the treatment of dementia
Burckhardt, M., Herke, M., Wustmann, T., Watzke, S., Langer, G., & Fink, A. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009002.pub3 · Cited by 178
Öhman, H., Savikko, N. M., Strandberg, T. E., Kautiainen, H., Raivio, M., Laakkonen, M., Tilvis, R. S., & Pitkälä, K. H. (2016) · Journal of the American Geriatrics Society · doi:10.1111/jgs.14059 · Cited by 172
Schneider, L. S., Insel, P. S., & Weiner, M. W. (2011) · Archives of Neurology · doi:10.1001/archneurol.2010.343 · Cited by 169
Raskind, M. A., Peskind, E. R., Truyen, L., Kershaw, P., & Damaraju, C. V. (2004) · Archives of Neurology · doi:10.1001/archneur.61.2.252 · Cited by 167
Howard, R., McShane, R., Lindesay, J., Ritchie, C., Baldwin, A., Barber, R., Burns, A., Dening, T., Findlay, D., Holmes, C., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00258-6 · Cited by 165
Laver, K., Dyer, S., Whitehead, C., Clemson, L., & Crotty, M. (2016) · BMJ Open · doi:10.1136/bmjopen-2015-010767 · Cited by 161
Knight, R., Khondoker, M., Magill, N., Stewart, R., & Landau, S. (2018) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000486546 · Cited by 161
Gamma Secretase Modulators: New Alzheimer’s Drugs on the Horizon?
Bursavich, M. G., Harrison, B. A., & Blain, J. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01960 · Cited by 151
What is the clinically relevant change on the ADAS-Cog?
Schrag, A., & Schott, J. (2011) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2011-300881 · Cited by 149
Schmidt, R., Hofer, E., Bouwman, F. H., Buerger, K., Cordonnier, C., Fladby, T., Galimberti, D., Georges, J., Heneka, M. T., Hort, J., et al. (2015) · European Journal of Neurology · doi:10.1111/ene.12707 · Cited by 140
Neuropathology after active Aβ42 immunotherapy: implications for Alzheimer’s disease pathogenesis
Boche, D., Denham, N., Holmes, C., & Nicoll, J. A. R. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0719-5 · Cited by 135
Exploring the relationship between physical activity, beta-amyloid and tau: A narrative review
Brown, B. M., Peiffer, J. J., & Rainey‐Smith, S. R. (2019) · Ageing Research Reviews · doi:10.1016/j.arr.2019.01.003 · Cited by 134
Toots, A., Littbrand, H., Boström, G., Hörnsten, C., Holmberg, H., Lundin‐Olsson, L., Lindelöf, N., Nordström, P., Gustafson, Y., & Rosendahl, E. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-170014 · Cited by 131
Effects of Physical Activity in Nursing Home Residents with Dementia: A Randomized Controlled Trial
Henskens, M., Nauta, I. M., van Eekeren, M. C. A., & Scherder, E. (2018) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000491818 · Cited by 125
Chen, R., Chan, P.-T., Chu, H., Lin, Y.-C., Chang, P., Chen, C., & Chou, K. (2017) · PLoS ONE · doi:10.1371/journal.pone.0183586 · Cited by 120
Jones, R. W., Soininen, H. S., Häger, K., Aarsland, D., Passmore, P., Murthy, A. K., Zhang, R., & Bahra, R. (2004) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.1038 · Cited by 118
A brief history of “Alzheimer disease”: Multiple meanings separated by a common name
Knopman, D. S., Petersen, R. C., & Jack, C. R. (2019) · Neurology · doi:10.1212/wnl.0000000000007583 · Cited by 118
The effect of physical exercise on cerebral blood flow in Alzheimer's disease
van der Kleij, L. A., Petersen, E. T., Siebner, H. R., Hendrikse, J., Frederiksen, K. S., Sobol, N. A., Hasselbalch, S. G., & Garde, E. (2018) · NeuroImage Clinical · doi:10.1016/j.nicl.2018.09.003 · Cited by 105
Vitamin E for Alzheimer's dementia and mild cognitive impairment
Farina, N., Llewellyn, D., Isaac, M. G. E. K. N., & Tabet, N. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002854.pub4 · Cited by 104
Matsunaga, S., Kishi, T., & Iwata, N. (2015) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyu115 · Cited by 104
Dong, X., Yan, L., Huang, L., Guan, X., Dong, C., Tao, H., Wang, T., Qin, X., & Wan, Q. (2018) · PLoS ONE · doi:10.1371/journal.pone.0205704 · Cited by 96
Safety and tolerability of donepezil 23 mg in moderate to severe Alzheimer’s disease
Farlow, M., Veloso, F., Moline, M., Yardley, J., Brand-Schieber, E., Bibbiani, F., Zou, H., Hsu, T., & Satlin, A. (2011) · BMC Neurology · doi:10.1186/1471-2377-11-57 · Cited by 95
Pirttilä, T., Wilcock, G. K., Truyen, L., & Damaraju, C. V. (2004) · European Journal of Neurology · doi:10.1111/j.1468-1331.2004.00885.x · Cited by 93
Cognitive performance in Alzheimer's disease patients receiving rivastigmine for up to 5 years
Small, G. W., Kaufer, D., Mendiondo, M. S., Quarg, P., & Spiegel, R. (2005) · International Journal of Clinical Practice · doi:10.1111/j.1368-5031.2005.00524.x · Cited by 91
Cholinesterase inhibitors for mild cognitive impairment
Russ, T. C., & Morling, J. R. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009132 · Cited by 90
Neuropsychiatric Symptoms Underlying Caregiver Stress and Insight in Alzheimer’s Disease
Rocca, P., Leotta, D., Liffredo, C., Mingrone, C., Sigaudo, M., Capellero, B., Rocca, G., Simoncini, M., Pirfo, E., & Bogetto, F. (2010) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000315513 · Cited by 88
NEURONAL COUNTS IN BASAL NUCLEUS OF MEYNERT IN ALZHEIMER DISEASE AND IN SIMPLE SENILE DEMENTIA
Tagliavini, F., & Pilleri, G. (1983) · The Lancet · doi:10.1016/s0140-6736(83)91462-9 · Cited by 84
Cholinesterase inhibitors for rarer dementias associated with neurological conditions
Li, Y., Hai, S., Zhou, Y., & Dong, B. R. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009444.pub3 · Cited by 78
Darreh‐Shori, T., Meurling, L., Pettersson, T., Hugosson, K. J. E., Hellström‐Lindahl, E., Andreasen, N. C., Minthon, L., & Nordberg, A. K. (2006) · Journal of Neural Transmission · doi:10.1007/s00702-006-0526-2 · Cited by 76
Normalization and the Cholinergic Microcircuit: A Unified Basis for Attention.
Schmitz, T., & Duncan, J. (2018) · Trends in Cognitive Sciences · doi:10.1016/j.tics.2018.02.011 · Cited by 76
Pharmacokinetic rationale for the rivastigmine patch
Cummings, J. L., Lefèvre, G. Y., Small, G. W., & Appel‐Dingemanse, S. (2007) · Neurology · doi:10.1212/01.wnl.0000281846.40390.50 · Cited by 72
Knapp, M. R. J., King, D., Romeo, R., Adams, J., Baldwin, A., Ballard, C. G., Banerjee, S., Barber, R., Bentham, P., Brown, R. G., et al. (2016) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.4583 · Cited by 68
024 What is the clinically relevant change on the ADAS-cog?
Schott, J. M., & Schrag, A. E. (2012) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2011-301993.66 · Cited by 67
Cholinesterase Inhibitor Discontinuation in Patients With Alzheimer’s Disease
O'Regan, J., Lanctôt, K. L., Mazereeuw, G., & Herrmann, N. (2015) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.14r09237 · Cited by 64
Jensen, C. S., Portelius, E., Siersma, V., Høgh, P., Wermuth, L., Blennow, K., Zetterberg, H., Waldemar, G., Hasselbalch, S. G., & Simonsen, A. H. (2016) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000449408 · Cited by 64
Herrmann, N., O'Regan, J., Ruthirakuhan, M. T., Kiss, A., Eryavec, G. M., Williams, E., & Lanctôt, K. L. (2015) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2015.08.019 · Cited by 60
Donepezil treatment in severe Alzheimer's disease: a pooled analysis of three clinical trials
Winblad, B. G., Black, S. E., Homma, A., Schwam, E. M., Moline, M. L., Xu, Y., Perdomo, C. A., Swartz, J., & Albert, K. S. (2009) · Current Medical Research and Opinion · doi:10.1185/03007990903236731 · Cited by 60
Zhong, Y., Zheng, X., Miao, Y., Yan, H., Wang, B., & Wan, L. (2012) · The American Journal of the Medical Sciences · doi:10.1097/maj.0b013e318255a8f9 · Cited by 58
An open-label, comparative study of rivastigmine, donepezil and galantamine in a real-world setting
Aguglia, E., Onor, M. L., Saina, M., & Maso, E. (2004) · Current Medical Research and Opinion · doi:10.1185/030079904x6273 · Cited by 52
Neuroanatomical Predictors of Response to Donepezil Therapy in Patients With Dementia
Csernansky, J. G., Wang, L., Miller, J. P., Galvin, J. E., & Morris, J. C. (2005) · Archives of Neurology · doi:10.1001/archneur.62.11.1718 · Cited by 49
Doody, R. S., Geldmacher, D., Farlow, M. R., Sun, Y., Moline, M. L., & Mackell, J. A. (2012) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000338236 · Cited by 47
Barreto, P. D. S., Andrieu, S., Payoux, P., Demougeot, L., Rolland, Y., Vellas, B. J., & the Multidomain Alzheimer Preventive Trial/Data Sharing Alzheimer Study Group (2015) · Journal of the American Geriatrics Society · doi:10.1111/jgs.13530 · Cited by 46
APOE-ɛ4 Carrier Status and Donepezil Response in Patients with Alzheimer’s Disease
Waring, J. F., Tang, Q., Robieson, W., King, D. P., Das, U., Dubow, J. S., Dutta, S., Marek, G. J., & Gault, L. M. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-142589 · Cited by 37
Tsoi, K. K. F., Chan, J. Y. C., Leung, N. W. Y., Hirai, H. W., Wong, S. Y. S., & Kwok, T. C. Y. (2016) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2016.05.015 · Cited by 37
LONG-TERM HEPATOTOXICITY OF TACRINE
Summers, W. K., Koehler, A. L., Marsh, G., Tachiki, K. H., & Kling, A. S. (1989) · The Lancet · doi:10.1016/s0140-6736(89)92246-0 · Cited by 36
A Nutritional Approach to Ameliorate Altered Phospholipid Metabolism in Alzheimer's Disease
Hartmann, T., van Wijk, N., Wurtman, R. J., Rikkert, M. G. M. O., Sijben, J., Soininen, H. S., Vellas, B. J., & Scheltens, P. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-141137 · Cited by 35
Sokolow, S., Li, X., Chen, L., Taylor, K. D., Rotter, J. I., Rissman, R. A., Aisen, P. S. S., & Apostolova, L. G. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160562 · Cited by 35
Homma, A., Atarashi, H., Kubota, N., Nakai, K., & Takase, T. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-151149 · Cited by 33
Coin, A., Pamio, M. V., Alexopoulos, C., Granziera, S., Groppa, F., de Rosa, G., Girardi, A., Sergi, G., Manzato, E., & Padrini, R. (2016) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-016-2033-1 · Cited by 32
Examining the reliability of ADAS-Cog change scores
Grochowalski, J. H., Liu, Y., & Siedlecki, K. L. (2015) · Aging Neuropsychology and Cognition · doi:10.1080/13825585.2015.1127320 · Cited by 31
Jiang, D.-Q., Yang, X., Li, M., Wang, Y., & Wang, Y. (2014) · Journal of Neural Transmission · doi:10.1007/s00702-014-1358-0 · Cited by 29
Rockwood, K. J., Howlett, S. E., Hoffman, D., Schindler, R. J., & Mitnitski, A. (2017) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2017.02.005 · Cited by 29
Concentration of Donepezil to the Cognitive Response in Alzheimer Disease
Yang, Y., Chen, C., Chou, M., Li, C.-H., Liu, C., & Chen, S. (2013) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31828b5087 · Cited by 28
Medical Foods for Alzheimerʼs Disease
Shah, R. C. (2011) · Drugs & Aging · doi:10.2165/11587380-000000000-00000 · Cited by 27
Gaudig, M., Richarz, U., Han, J., van Baelen, B., & Schäuble, B. (2011) · Current Alzheimer Research · doi:10.2174/156720511797633205 · Cited by 25
Ohnishi, T., Sakiyama, Y., Okuri, Y., Kimura, Y., Sugiyama, N., Saito, T., Takahashi, M., & Kobayashi, T. (2014) · Current Alzheimer Research · doi:10.2174/15672050113106660167 · Cited by 23
Han, H. J., Kwon, J. C., Kim, J. E., Kim, S. G., Park, J., Park, K. W., Park, K., Park, K. H., Moon, S. Y., Seo, S. W., et al. (2014) · European Neurology · doi:10.1159/000366198 · Cited by 23
Fukui, T., & Taguchi, S. (2005) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000085069 · Cited by 18
Kishi, T., Matsunaga, S., Oya, K., Ikuta, T., & Iwata, N. (2015) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyv070 · Cited by 18
Cheng, Y., Huang, Y., & Liu, H. (2018) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000490175 · Cited by 15
Tsoi, K. K. F., Hirai, H. W., Chan, J. Y. C., & Kwok, T. C. Y. (2015) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2015.08.007 · Cited by 14
Two galantamine titration regimens in patients switched from donepezil
Engedal, K., Davis, B. J., Richarz, U., Han, J., Schäuble, B., & Andreasen, N. C. (2011) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.2011.01594.x · Cited by 13
Adverse Events With Sustained-Release Donepezil in Alzheimer Disease
Lee, C., Lee, K., Yu, H., Ryu, S., Moon, S. W., Han, C., Lee, J., Lee, Y. M., Kim, S. G., Kim, K. W., et al. (2017) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000726 · Cited by 11
Efficacy and Safety of Donepezil in Patients With Alzheimer’s Disease in Assisted Living Facilities
Rosenblatt, A., Gao, J., Mackell, J. A., & Richardson, S. (2010) · American Journal of Alzheimer s Disease & Other Dementias® · doi:10.1177/1533317510372923 · Cited by 8
Cited by
Efficacy of acetylcholinesterase inhibitors in Alzheimer’s disease.
Marucci, G., Buccioni, M., Ben, D. D., Lambertucci, C., Volpini, R., & Amenta, F. (2021) · Neuropharmacology · doi:10.1016/j.neuropharm.2020.108352 · Cited by 1,147
Zhang, J., Zhang, Y., Wang, J., Xia, Y., Zhang, J., & Chen, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01911-3 · Cited by 1,138
Alzheimer’s disease: Recent treatment strategies
Vaz, M., & Silvestre, S. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173554 · Cited by 547
Hypoxia and brain aging: Neurodegeneration or neuroprotection?
Burtscher, J., Mallet, R. T., Burtscher, M., & Millet, G. P. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101343 · Cited by 324
Xu, M., Feng, T., Liu, B., Qiu, F., Xu, Y., Zhao, Y., & Zheng, Y. (2021) · Theranostics · doi:10.7150/thno.62330 · Cited by 229
Metadata
- Authors
- Joe, E., & Ringman, J. M.
- Venue
- BMJ
- Publisher
- BMJ
- Published
- 2019-12-06
- Volume
- 367
- Pages
- l6217
- ISSN
- 1756-1833 (ISSN-L)
- OpenAlex
- W2993041426
- Cited by
- 321
- References
- 126
- FWCI
- 24.42
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.